In gliomas, both AQP1 and AQP4, when suppressed, offer a better prognosis for patients affected by these types of tumors by edema reduction (Faraj et al., 2022; Ohmura et al., 2023), facilitating the management of neurological deficits in the pre-and postoperative periods, with peritumoral edema being more relevant, in terms of concerns the aggressiveness of this cancer, rather than its extent, per se (Faraj et al., 2022). The gene discussed is AQP4; the disease is central nervous system cancer.